Prostate News Archive
05-Nov-2007
Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference ... (PR Newswire via Yahoo! Finance)
Medivation, Inc. today announced that it will announce early positive data from the ongoing Phase 1-2 trial of the company's selective androgen receptor modulator, MDV3100, in hormone refractory prostate cancer before the markets open on Monday, November 5, 2007. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference ... (FinanzNachrichten)
SAN FRANCISCO, Nov. 3 /PRNewswire-FirstCall/ -- Medivation, ( Nachrichten ) Inc. today announced that it will announce early positive data from the ongoing Phase 1-2 trial of the company's selective androgen receptor modulator, MDV3100, in hormone refractory prostate cancer before the markets open on Monday, November 5, 2007. A conference call and live webcast will be held at 8:30 a.m. Eastern ... Guiliani Annoys Brits With Outdated Prostate Cancer Statistics (Medical News Today)
As Rudy Guiliani quotes outdated prostate cancer survival rates in the United Kingdom, and compares it with up-to-date US figures relevant only to Americans with health care cover, members of the British government have expressed annoyance at these underhand tactics. [click link for full article]
Back to Prostate News Archive
